News

Based on the assessment, progression-free survival (PFS) will be the primary endpoint of the Phase III trial and overall survival will be a secondary endpoint. The company expects

MB07133 is a novel HepDirect prodrug of cytarabine monophosphate (araCMP) designed to produce the oncolytically active form cytarabine triphosphate (araCTP) in the liver tumor, where it acts to

The Phase II single-agent study is being conducted at multiple centers across the US to evaluate the safety and efficacy of MKC-1 in metastatic breast cancer patients who

<p>A US district court in Connecticut granted Applied Biosystems&#0039;s summary judgment motion, dismissing all remaining patent infringement claims filed by Enzo.<br /><br />The company had been seeking royalties

Cervical intraepithelial neoplasia (CIN) is the abnormal growth of precancerous cells in the cervix, usually caused by infection with human papillomavirus (HPV). In addition to the key objective

In the study, the drug showed a clinically and statistically significant reduction in the number of hereditary angioedema (HAE) attacks. Based on the positive results of this study,

The companies mutually agreed to end their collaborative development and marketing agreement on bremelanotide, with King exercising its right to terminate. Under the termination, Palatin has all rights

Bioniche said that the agreement had been reached under the FDA's special protocol assessment (SPA) procedure. The company plans to evaluate its proprietary mycobacterial cell wall-DNA complex (MCC),

The US district court in New Jersey denied the motion for a preliminary injunction by drugmakers Wyeth and Altana who were aiming to stop Israel-based Teva from launching